{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-027863","form_type":"8-K","ticker":"MBRX","cik":"0001659617","company_name":"Moleculin Biotech, Inc.","filed_at":"2023-10-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.971879+00:00","generated_at":"2026-06-10T03:30:31.862723+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Moleculin Biotech shareholders approve reverse stock split authorization at special meeting","bullets":["Reverse split proposal approved: 9,796,443 For, 6,858,043 Against, 170,202 Abstain.","Board authorized to choose ratio between 1-for-5 and 1-for-20 within one year.","Adjournment proposal also approved: 10,036,330 For, 6,686,830 Against, 101,528 Abstain.","Board has not yet decided whether to implement a reverse split as of filing date."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-027863","json":"https://secwatch.observer/filing/0001437749-23-027863.json","markdown":"https://secwatch.observer/filing/0001437749-23-027863.md","text":"https://secwatch.observer/filing/0001437749-23-027863.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1659617/000143774923027863/0001437749-23-027863-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1659617/000143774923027863/mbrx20231003_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T03:30:31.862723+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"beb60c19dfbfe38f861dd6ea7b083e3cc2906b5b","claim":"Moleculin Biotech, Inc. shareholders approved Approve an Adjournment - The Company's stockholders approved an adjournment, if necessary, to solicit additional proxies if there are not sufficient votes in favor of the Reverse Split Proposal at the 2023-10-03 meeting.","evidence_excerpt":"Proposal 2. Approve an Adjournment - The Company's stockholders approved an adjournment, if necessary, to solicit additional proxies if there are not sufficient votes in favor of the Reverse Split Proposal (the “Adjournment Proposal”), by the following vote: Votes For Votes Against Abstain 10,036,330 6,686,830 101,528","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1659617/000143774923027863/0001437749-23-027863-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"reverse split"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-10-03"}],"fact_type":"shareholder_vote"},{"claim_id":"d439be3c26fc051c0b432a0e9e2f7fdda5b1fde0","claim":"Moleculin Biotech, Inc. shareholders approved To Effect a Reverse Stock Split of the Outstanding Shares - The Company's stockholders approved an amendment to the Company’s amended and restated certificate of incorporation to grant the Board of Directors authority to effect a reverse stock split of the outstanding shares of the Company’s common at the 2023-10-03 meeting.","evidence_excerpt":"Proposal 1. To Effect a Reverse Stock Split of the Outstanding Shares - The Company's stockholders approved an amendment to the Company’s amended and restated certificate of incorporation to grant the Board of Directors authority to effect a reverse stock split of the outstanding shares of the Company’s common stock, at a reverse stock split ratio of between 1-for-5 and 1-for-20 as determined by the Board in its sole discretion, prior to the one-year anniversary of this Special Meeting (the “Reverse Split Proposal”), by the following vote: Votes For Votes Against Abstain 9,796,443 6,858,043 170,202","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1659617/000143774923027863/0001437749-23-027863-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"reverse split"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-10-03"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}